SPORE Publications by Investigators

Grant Cycle Two (2007-2012)

Publications

  1. Bentov I, Narla G, Schayek H, Akita K, Plymate SR, LeRoith D, Friedman SL, Werner H. Insulin-like growth factor-I regulates Kruppel-like factor-6 gene expression in a p53-dependent manner. Endocrinology. 2008 Apr;149(4):1890-7.
    PMID: 18174288
  2. Black PC, Mize GJ, Karlin P, Greenberg DL, Hawley SL, True LD, Vessella RL and Takayama TK.   Overexpression of protease-activated receptors -1, -2, and -4 (PAR -1, -2, and -4) in prostate cancer. Prostate. 67:743-756, 2007.
    http://www3.interscience.wiley.com/cgi-bin/fulltext/114190126/PDFSTART
  3. Bonfil RD, Dong Z, Trindade Filho JC, Sabbota A, Osenkowski P, Nabha S, Yamamoto H, Chinni SR, Zhao H, Mobashery S, Vessella RL, Fridman R, and Cher ML.  Prostate cancer-associated membrane type 1-matrix metalloproteinase.  A pivotal role in bone response and intraosseous tumor growth. Am J Pathol., 170:2100-2111, 2007.
    http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1899437&blobtype=pdf
  4. Chen C, Sun X, Guo P, Dong XY, Sethi P, Zhou W, Zhou Z, Petros J, Frierson HF, Vessella RL, Atfi A, and Dong JT.  Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer.  Oncogene 26:2386-2394, 2007.
    http://www.nature.com/onc/journal/v26/n16/pdf/1210021a.pdf
  5. Cherrier MM, Aubin S, Higano CS.  Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer.  Psycooncology  2008 Jul 17. [Epub ahead of print]
    PMID: 18636420
  6. Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol. 2008 Aug;180(2):565-70; discussion 570
    PMID: 18554663
  7. Chi, KN, Siu, LL, Hirte H, Hotte SJ, Knox J, Kollmansberger C, Gleave ME, Guns ES, Power J, Walsh W, Tu D, Eisenhauer E. A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.  Clin Cancer Res 2008 Feb 1;14(3):833-9.
    PMID: 18245546
  8. Cochrane DR, Wang Z, Muramaki M, Gleave ME, Nelson CC.  Differential regulation of clusterin and its isoforms by androgens in prostate cells. Journal of Biological Chemistry 2007; 282(4):2278-87
    PMID: 17148459
  9. Datta MW, True LD,  Nelson PS, Amin MB. The role of tissue microarrays in prostate cancer biomarker discovery. Adv Anat Pathol.14(6):408-418, 2007.
    PMID: 18049130
  10. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL and Tindall DJ.  Splicing of a novel AR exon generates a constituitively active androgen receptor that mediates prostate cancer therapy resistance.   Can Research 2008 2008 Jul 1;68(13):5469-77
    PMID: 18593950
  11. Dong XY, Rodriguez C, Guo P, Sun X, Talbot JT, Zhou W, Petros J, Li !, Vessella RL, Kibel AS, Stevens VI, Calle EE, and Dong JT.  SnoRNA U50 is a candidate tumor suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer.  Hum Mol Genet 17:1031-1042, 2008.
    http://hmg.oxfordjournals.org/cgi/reprint/17/7/1031
  12. Festuccia C, Gravina GL, Muzi P, Pomante R, Ventura L, Vessella RL, Vicentini C, Bologna M.  Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer.   Endocr Relat Cancer 14:601-611, 2007. 
    http://erc.endocrinology-journals.org/cgi/reprint/14/3/601
  13. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR.  Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men.  Cancer 2007; 109(6):1192-202.
    PMID 17311344
  14. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR.  Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men.  Cancer Causes Control 2008;19:25-31.
    PMID 17906959
  15. Hadaschik BA, Jackson J, Fazli L, Zoubeidi A, Burt HM, Gleave ME, So AI. Intravesically administered antisense oligonucleotides targeting HSP27 inhibit the growth of nonmuscle-invasive bladder cancer. BJU Int., 2008 Aug 5;102(5):610-6
    PMID: 18384625
  16. Holcomb IN, Grove DI, Kinnunen M, Friedman C, Gallaher I, Morgan TM, Sather CL, Delrow JJ, Nelson PS, Lange PH, Ellis WJ, True LD, Young JM, Hsu L, Trask BJ, Vessella RL et al. Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Res.  2008 Jul 15;68(14):5599-608
    PMID: 18632612
  17. Holt SK, Karyadi DM, Kwon EM, Stanford JL, Nelson PS, Ostrander EA.  Association of megalin genetic polymorphisms with prostate cancer risk and prognosis.  Clin Cancer Res 2008 Jun 15;14(12):3823-31
    PMID: 18559602
  18. Huang Y, Pepe M, Feng Z. Evaluating the predictiveness of a continuous marker. Biometrics 2007;63:1181-1188.
    PMID: 17489968.
  19. Huang CY, Beer TM, Higano CS, True LD, Vessella R, Lange PH, Garzotto M and Nelson PS.  Molecular alterations in prostate carcinoma that associate with in vivo exposure to chemotherapy:  identification of a cytoprotective mechanism involving growth differentiation factor 15.  Clin Cancer Res 13:5825-5833, 2007.
    http://clincancerres.aacrjournals.org/cgi/reprint/13/19/5825
  20. Inoue LY, Neira M, Nelson C, Gleave M, Etzioni R. Cluster-based network model for time-course gene expression data. Biostatistics. 2007 Jul;8(3):507-25.
    PMID: 16980695
  21. Kalhorn TF, Page ST, Howald WN, Mostaghel EA, Nelson PS. Analysis of testosterone and dihydrotestosterone from biological fluids as the oxime derivatives using high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2007;21(19):3200-6.
    PMID: 17764104
  22. Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD, Nelson PS, Vasioukhin V. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A. 105(6):2105-2110, 2008.
    http://www.pnas.org/cgi/reprint/105/6/2105
  23. Knudsen BS, Allen AN, McLerran DF, Vessella RL, Karademos J, Davies JE, Maqsodi B, McMaster GK and Kristal AR.   Evaluation of the branched chain DNA assay for measurement of RNA in formalin-fixed tissues.   Mol. Diagn 10:169-176, 2008.
    http://jmd.amjpathol.org/cgi/reprint/10/2/169
  24. Lin B, Utleg AG, Graydal K, White JT, Lalvorsen OJ, Lu W, True LD, Vessella RL, Lange PH, Nelson PS, Hood L, Kalland KH and Aksien LA.  WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence.   Clin Cancer Res. 14:1397-1406, 2008.
    http://clincancerres.aacrjournals.org/cgi/reprint/14/5/1397
  25. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Research 2008 Aug 1;68(15):6407-15.
    PMID: 18676866
  26. Locke JA, Wasan KM, Nelson CC, Guns ES  Leon C. Androgen-mediated cholesterol metabolism in LNCaP and PC-3 cell lines is regulated through two different isoforms of acyl-coenzyme a:cholesterol acyltransferase (ACAT).  Prostate 2008 Jan 1; 68(1):20-33
    PMID: 18000807
  27. Lucas J, True L, Hawley S, Matsumura M, Morrissey C, Vessella R and Nelson P.  The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.  J Pathol, 215:118-125, 2008.
    http://www3.interscience.wiley.com/cgi-bin/fulltext/117899645/PDFSTART
  28. Maki H, Saramaki O, Martikainen P, Tammela T, van Weerden W, Vessella R, Cato A and Visakorpi T.  Overexpression and gene amplification of BAG-1L in hormone refractory prostate cancer.  J Pathol. 212:395-401, 2007.
    http://www3.interscience.wiley.com/cgi-bin/fulltext/114262997/PDFSTART
  29. Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S, Tchinda J, Laxman B, Vessella RL, Beroukhim R, Lee C, Chinnaiyan AM, and Rubin MA. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia. 9:200-206, 2007.
    http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1838578&blobtype=pdf
  30. Montgomery RB, Nelson PS, Lin D, Ryan CW, Garzotto M, Beer TM. Diethylstilbestrol and docetaxel: a phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer. Cancer. 2007 Sep 1;110(5):996-1002.
    PMID: 17639587
  31. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008 Jun 1;68(11):4447-54
    PMID: 18519708
  32. Morgan T, Lange PH and Vessella RL. Detection and characterization of circulating and disseminated prostate cancer cells.   Front Biosci, 2007 May 1;12:3000-9.
    PMID: 17485277
  33. Morgan TM, Pitts TE, Gross TS, Poliachik SL, Vessella RL and Corey E.  RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and Zoledronic acid.   Prostate, 68:861-871, 2008. 
    http://www3.interscience.wiley.com/cgi-bin/fulltext/117946209/PDFSTART
  34. Morrissey C, True LD, Roudier MP, Coleman IM, Hawley S, Nelson PS, Coleman R, Wang Y, Corey E, Lange PH, Higano CS and Vessella RL.  Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases.  Clin Exp Metastases 2008;25(4):377-88. Epub 2007 Oct 31
    http://www.springerlink.com/content/r75g514q527515n4/fulltext.pdf
  35. Mostaghel EA, Page ST, Lin DW, Fazli F, Coleman I, True LD, Knudsen B, Hess DL, Nelson C, Matsumoto AM, Bremner WJ, Gleave M, Nelson PS, Intraprostatic Androgens and Androgen-Regulated Gene Expression Persist Following Testosterone Suppression: Therapeutic Implications for Castration-Resistant Prostate Cancer. Cancer Res.  67(10):5033-5041, 2007.
    PMID: 17510436
  36. Pepe MS, Feng Z, Huang Y, Longton G, Prentice R, Thompson IM, Zheng Y. Integrating the predictiveness of a marker with its performance as a classifier. American Journal of Epidemiology 2008;167(3):362-368.
    PMID: 17982157.
  37. Pfitzenmaier J, Ellis WJ, Hawley S, Arfman EW, Klein JR, Lange PH, and Vessella RL.  The detection and isolation of viable PSA positive epithelial cells by enrichment:  a comparison to standard PSA RT-PCR and its clinical relevance in prostate cancer.  Urologic Oncology, 25:214-220, 2007.
    PMID: 17483018
  38. Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, soule HR, Bandyke TA, Weber MJ, Wu L and Vessella RL.  The current state of preclinical prostate cancer animal models.   Prostate 68:629-639, 2008.
    http://www3.interscience.wiley.com/cgi-bin/fulltext/117891907/PDFSTART
  39. Pierce BL, Plymate S, Ostrander EA, Stanford JL. Diabetes mellitus and prostate cancer risk.
    Prostate. 2008 Jul 1;68(10):1126-32
    PMID: 18459104
  40. Plymate SR, Haugk K, Coleman I, Wooke L, Vessella RL, Nelson P, Montgomery RB, Ludwig DL, and Wu JD.   An antibody targeting the type 1 insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer.  Clin Cancer Res 12:6429-6439, 2007.
    http://clincancerres.aacrjournals.org/cgi/reprint/13/21/6429
  41. Porkka KP, Pfeiffer M, Waltering KK, Vessella RL, Tammela TLJ and Visakorpi T.  MicroRNA expression profiles in prostate cancer.  Cancer Res. 67:6130-6135, 2007.
    http://cancerres.aacrjournals.org/cgi/reprint/67/13/6130
  42. Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL, Ott SM.  Histopathologic assessment of prostate cancer bone "osteoblastic" metastasis. J Urol 2008 Sep;180(3):1154-60
    PMID: 18639279
  43. Salinas CA, Kwon E, Carlson CS, Koopmeiners JS, Feng Z, Karyadi DM, Ostrander EA, Stanford JL.  Multiple independent genetic variants in the 8q24 region are associated with prostate cancer risk.  Cancer Epidemiol Biomarkers Prev 2008; 17(5):1203-13.
    PMID 18483343
  44. Salinas CA, Koopmeiners JS, Kwon E, Fitzgerald L, Lin DW, Ostrander EA, Feng Z, Stanford JL. Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate 2009 Mar 1;69(4):363-72
    PMID: 19058137
  45. Sim HG, Telesca D, Culp SH, Ellis WJ, Lange PH, True LD, Lin DW.  Tertiary Gleason Pattern 5 in Gleason 7 Prostate Cancer Predicts Pathological Stage and Biochemical Recurrence. J Urol. 179(5):1775-1779, 2008.
    PMID: 18343432
  46. So A, Hadaschik B, Sowery R, Gleave ME. The role of stress proteins in prostate cancer. Current Genomics 2007 Jun;8(4):252-61.
    PMID: 18645594
  47. Sokoll LJ, Ellis W, Lange PH, Noteboom J,  Elliott DJ, Deras IL,  Blasé A, Koo S, Sarno M, Rittenhouse H, Groskopf J, and Vessella RL.  A multicenter evaluation of the PCA3 molecular urine test: preanalytical effects, analytical performance, and diagnostic accuracy.  Clinica Chimica Acta 389:1-6, 2008.
    PMID: 18061575
  48. Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A, Gleave ME. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int., 2008 Aug;102(3):389-97
    PMID: 18336596
  49. Sprenger CC, Plymate SR, Reed MJ. Extracellular influences on tumour angiogenesis in the aged host. Br J Cancer. 2008 Jan 29;98(2):250-5. Epub 2008 Jan 8. Review.
    PMID: 18182993
  50. Springate CM, Jackson JK, Gleave ME, Burt HM. Clusterin antisense complexed with chitosan for controlled intratumoral delivery. Int J Pharm. 2008 Feb 28; 350(1-2):53-64.
    PMID: 17890029
  51. Telesca D. and Inoue L.Y.T. (2008). Bayesian Hierarchical Curve Registration. Journal of The American Statistical Association, Volume 103, Number 481, pp. 328-339(12).
    http://pubs.amstat.org/doi/pdf/10.1198/016214507000001139
  52. Telesca D., Inoue L.Y.T., Neira M., Etzioni, R., Gleave M., Nelson, C. Differential expression and network inferences through functional data modeling. Biometrics 2008 Nov 13. [Epub ahead of print]
    PMID: 19053995
  53. Tillman JE, Yuan J, Gu G, Fazli L, Ghosh R, Flynt AS, Gleave M, Rennie PS, Kasper S. DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells. Cancer Research 2007 May 15;67(10):4630-7
    PMID: 17510388
  54. True LD, Jordan CD. The cancer nuclear microenvironment: Interface between light microscopic cytology and molecular phenotype. J Cell Biochem 2008 Aug 15;104(6):1994-2003
    http://www3.interscience.wiley.com/cgi-bin/fulltext/117347538/HTMLSTART
  55. True LD, Gao X. Quantum dots for molecular pathology: their time has arrived. J  Molecular Diagnostics. 9:7-11, 2007.
    http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2248800&blobtype=pdf
  56. Wikman H, Vessella RL, Pantel K. Cancer micrometastasis and tumour dormancy.  APMIS 2008 Jul-Aug;116(7-8):754-70
    PMID: 18834417
  57. Yapp DT, Woo J, Kartono A, Sy J, Oliver T, Skov KA, Koch CJ, Adomat H, Dragowska WH, Fazli L, Ruth T, Adam MJ, Green D, Gleave M. Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with (18)F-EF5 and positron emission tomography. BJU Int. 2007 May;99(5):1154-60. Epub 2007 Feb 19.
    PMID: 17309552
  58. You Z, Dong Y, Kong X, Zhang Y, Vessella RL, and Melamed J.  Differential expression of IL-17RC isoforms in androgen-dependent and androgen-independent prostate cancers.  Neoplasia 9:464-470, 2007.
    http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1899256&blobtype=pdf
  59. Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P, Nelson C, Gleave M. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 2007 Nov 1;67(21):10455-65
    PMID: 17974989

Book Chapters

  1. Hadaschik BA, Gleave ME. Chapter 25 - Antisense oligonucleotides for the treatment of cancer. pps 699-720 Second Edition, Antisense Drug Technology Principles, Strategies and Applications; Stanley T. Crooke, Editor 2007

Meetings

  1. Cherrier M, Higano CS, Johnson M, Cross DJ, Minoshima S.  Decreased cerebral metabolism from androgen suppression.  IMPaCT: Innovative Minds in Prostate Cancer Today, Atlanta, GA, Sept 5-8, 2007.
  2. Cherrier MM, Green P, Schellenberg GS, Higano CS.  Association of apolipoprotein E on serum abeta levels in men undergoing intermittent androgen ablation.  2008 Alzheimer's Association International Conference on Alzheimer's Disease, Chicago, IL.
  3. Gulati R, Yu EY, Telesca D, Jiang P, Montgomery RB, Tam S, Russell KJ, Nelson PS, Etzioni RB, Higano CS.  Testosterone kinetics in the first cycle of intermittent androgen deprivation for men with localized or biochemical relapse of prostate cancer.  2008 ASCO Annual Meeting, Chicago, IL.
  4. Mostaghel EA, Montgomery RB, Vessella R, Kalhorn T, True L, Higano C, Nelson PS.  Correlating androgen levels and steroidogenic enzyme expression in castration resistant prostate cancer metastases.  2008 ASCO Genitourinary Symposium, San Francisco, CA.
  5. Telesca D, Higano CS, Yu EY, Montgomery RB, Tam S, Russell KJ, Nelson PS, Etzioni RB.  Duration of the first off treatment period is associated with time to androgen independence (AI) and survival in men with localized or biochemical relapse of prostate cancer treated on prospective trial of intermittent androgen deprivation (IAD).  2007 ASCO Annual Meeting, Chicago, IL. J Clin Oncol  2007 ASCO Annual Meeting Proceedings Part I. 25(18S):5146.
  6. Wright JL, Lange PH, Ellis WJ, True LD, Lin DW.  Clinicopathologic predictors of tertiary Gleason pattern 5 in radical prostatectomy specimens.  2008 American Urological Association, Orlando, FL.  J Urol  2008 179(4 suppl): 54-55.

Fred Hutchinson Cancer Research Center
1100 Fairview Ave. N. PO Box 19024 Seattle, WA 98109
©2009 Fred Hutchinson Cancer Research Center, a nonprofit organization.
Terms of Use & Privacy Policy.

CenterNetCheck E-mail